FDA Clears Osmetech's Warfarin Sensitivity Test | GenomeWeb
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Osmetech’s eSensor Warfarin Sensitivity Test, the London-based firm announced today.
 
The genetic test is used to aid physicians in identifying patients who are at risk for increased sensitivity to the blood-thinning drug warfarin. Osmetech submitted its application with the FDA for the test at the beginning of this year.
 
The firm said that the FDA also cleared its second-generation eSensor XT-8 molecular diagnostics platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.